Assurant
AIZ · Multi-line Insurance
$284.75
1.4%RenaissanceRe
RNR · Reinsurance
$352.60
2.8%The short version
- RenaissanceRe is the larger business, with $12.8B of revenue in fiscal 2025 against $12.8B for Assurant.
- RenaissanceRe grew revenue faster (9.9%, against 7.9%).
- RenaissanceRe earned a higher return on the capital invested in it (54.2%, against 17.5%).
| Latest fiscal year | AIZ · FY25 | RNR · FY25 |
|---|---|---|
| Size | ||
| Market cap | $14.2B | $14.6B |
| Revenue | $12.8B | $12.8B |
| Free cash flow | $1.6B | — |
| Net income | $873M | $2.7B |
| Growth | ||
| Revenue growth | 7.9% | 9.9% |
| 5-year growth | 6.0% | 20.0% |
| Share count change | −1.9% | −9.5% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | 6.8% | 20.9% |
| FCF margin | 12.5% | — |
| Return on capital | 17.5% | 54.2% |
| Return on equity | 15.9% | 24.2% |
| Balance sheet | ||
| Net debt | −$6.7M | −$4.1B |
| Net debt / EBITDA | 0.0x | −1.0x |
| Dividends and buybacks | $472M | $1.7B |
| Valuation & quality | ||
| P/E | 13.6x | — |
| Piotroski F-score | — | — |
FY16
AIZ $7.5B
RNR $1.7B
FY17
AIZ $6.4B
RNR $2.1B
FY18
AIZ $8.1B
RNR $2.1B
FY19
AIZ $9.6B
RNR $4.2B
FY20
AIZ $9.6B
RNR $5.2B
FY21
AIZ $10.2B
RNR $5.3B
FY22
AIZ $10.2B
RNR $5.1B
FY23
AIZ $11.1B
RNR $9.1B
FY24
AIZ $11.9B
RNR $11.7B
FY25
AIZ $12.8B
RNR $12.8B
AIZ
RNR
FY16
AIZ —
RNR —
FY17
AIZ —
RNR —
FY18
AIZ —
RNR —
FY19
AIZ —
RNR —
FY20
AIZ —
RNR —
FY21
AIZ —
RNR —
FY22
AIZ —
RNR —
FY23
AIZ —
RNR —
FY24
AIZ —
RNR —
FY25
AIZ —
RNR —
AIZ
RNR
FY16
AIZ $23.4M
RNR —
FY17
AIZ $468M
RNR —
FY18
AIZ $574M
RNR —
FY19
AIZ $1.3B
RNR —
FY20
AIZ $1.2B
RNR —
FY21
AIZ $594M
RNR —
FY22
AIZ $411M
RNR —
FY23
AIZ $936M
RNR —
FY24
AIZ $1.1B
RNR —
FY25
AIZ $1.6B
RNR —
AIZ
RNR
FY16
AIZ 15.5%
RNR 16.8%
FY17
AIZ 12.4%
RNR −6.4%
FY18
AIZ 6.9%
RNR 11.5%
FY19
AIZ 7.0%
RNR —
FY20
AIZ 11.1%
RNR —
FY21
AIZ 12.5%
RNR —
FY22
AIZ 7.2%
RNR —
FY23
AIZ 15.1%
RNR —
FY24
AIZ 16.8%
RNR 54.4%
FY25
AIZ 17.5%
RNR 54.2%
AIZ
RNR
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.